Cytokinetics, Incorporated (NASDAQ:CYTK) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET
Company Participants
Diane Weiser - Senior Vice President of Corporate Communications & Investor Relations
Robert Blum - President & Chief Executive Officer
Fady Malik - Executive Vice President, Research & Development
Steve Heitner - VP:Clinical Research & Therapeutic Area Lead at Cytokinetics Inc.
Andrew Callos - Executive Vice President & Chief Commercial Officer
Robert Wong - Vice President & Chief Accounting Officer
Ching Jaw - Senior Vice President & Chief Financial Officer
Conference Call Participants
Jason Butler - JMP
Jason Zemansky - BofA.
Joe Pantginis - H.C. Wainwright
Yasmeen Rahimi - Piper Sandler
Salim Syed - Mizuho
Justin Kim - Oppenheimer
Srikripa Devarakonda - Truist Securities
Operator
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics Second Quarter 2020 Conference Call. [Operator Instructions] I'll now turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Diane Weiser
Good afternoon, and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Fady Malik, EVP of R&D, will provide updates related to aficamten focused to SEQUOIA-HCM, REDWOOD-HCM and FOREST-HCM;, VP, Clinical Research and Therapeutic Area lead, Cardiovascular, is filling in for Stuart Kupfer today, and we'll provide additional updates for aficamten relating to MAPLE-HCM and speak to the expected start of Acacia HCM. Andrew Callos, EVP and Chief Commercial Officer, will speak about commercial readiness activities for aficamten and its market opportunity. Robert Wong, VP and Chief Accounting Officer, will provide a financial overview of the past quarter; and Ching Jaw, SVP and Chief Financial Officer, will discuss our financial outlook and revised spending guidance for 2023. Finally, Robert Blum will provide an update on our early clinical programs in his closing comments and review expected upcoming milestones.
Please note that portions of the following discussion, including our responses to questions, contain statements that relate to future events and performance rather than historical facts and constitute forward-looking statements. Our actual results might differ materially from those projected in these forward-looking statements. Additional information concerning factors that could cause our actual results to differ materially from those in these forward-looking statements is contained in our SEC filings, including our current report regarding our second quarter 2023 financial results filed on Form 8-K that was furnished to the SEC today. We undertake no obligation to update any forward-looking statements after this call.